BioSpace News Archive

Avadel Pharmaceuticals plc announced today the publication of positive secondary endpoint data from its pivotal Phase 3 REST-ON trial of FT218 in CNS Drugs, a peer-reviewed medical journal focused on the treatment of psychiatric and neurological disorders.

Merus N.V. announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 10:15-10:55 a.m. ET.

Ocuphire Pharma, Inc. announced that Mina Sooch, MBA, Founder and CEO, will review the opportunity for APX3330, a Phase 2b oral small molecule inhibitor of novel target Ref-1 in diabetic eye disease at the Wet AMD & DME Drug Development Summit today, Wednesday, April 6 in Boston, MA.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the enrollment of the last subject in its ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and adults with scalp and body psoriasis.

Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leader Aaron Pelta promoted to Senior Vice President, Business and Corporate Development; leading portfolio, commercial, and partnering strategy.

Direct Biologics announces topline results from its first-in-human, multicenter, Phase II double-blind, placebo-controlled, randomized clinical trial, EXIT COVID-19,

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced that it will present new Phase 2 US clinical study data regarding its lead drug candidate, EC-18 for chemoradiation-induced oral mucositis (CRIOM) at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, which will be held in-person on June 3-7th, 2022 in Chicago.

Stella Diagnostics, Inc. today announced it will be giving a data presentation this week at the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8 – 13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.

Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares of its common stock at a purchase price of $5.27 per share in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of $7.0 million before deducting placement agent fees and expenses.

Intrommune Therapeutics today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow determination of the Maximum Tolerated Dose (MTD).